Published in Cancer Weekly, December 19th, 2006
Intradigm was formed in 2000 to develop proprietary nucleic acid delivery technology. The fundamental platform of Intradigm's technology is a ligand-targeted nanoparticle system that is capable of systemic delivery of multiple RNA interference (RNAi) molecules targeting different genes.
"The discovery that RNAi can silence gene expression is a major scientific breakthrough, and has led...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-12-19)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.